Actinium Pharmaceuticals (ATNM) Stock Price, News & Analysis

Company Overview

Actinium Pharmaceuticals, Inc. is a biotechnology company focused on developing targeted radiotherapies for patients with hematologic malignancies, particularly those with relapsed or refractory disease. The company’s approach uses monoclonal antibodies to deliver radioactive isotopes directly to cancer cells, with the goal of selectively destroying malignant cells while limiting damage to healthy tissue.

Actinium’s leading investigational product is Iomab-B, also known as iodine-131 apamistamab. It is designed as a targeted conditioning treatment to prepare patients with relapsed or refractory acute myeloid leukemia for a bone marrow transplant. The company is also developing additional antibody-based radioimmunotherapies, including programs directed at blood cancers such as acute myeloid leukemia and multiple myeloma.

Actinium Pharmaceuticals is headquartered in New York City and conducts its development activities through clinical research programs in the United States and other locations. Sandesh Seth serves as the company’s chairman and chief executive officer.

Key Stats

• Today's Range: $1.55 to $1.63
• 50-Day Range: $0.97 to $1.60
• 52-Week Range: $0.74 to $1.72
• Volume: 108,580 shs
• Average Volume: 157,243 shs
• Market Capitalization: $49.68 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $5.00
• Consensus Rating: Buy

Actinium Pharmaceuticals Stock Analysis - MarketRank™

Actinium Pharmaceuticals scored higher than 42% of companies evaluated by MarketBeat, and ranked 662nd out of 892 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.5 / 5
• Analyst Rating: Buy

Consensus Rating

Actinium Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on no strong buy ratings, 1 buy rating, no hold ratings, and no sell ratings.

Upside Potential

Actinium Pharmaceuticals has a consensus price target of $5.00, representing about 217.5% upside from its current price of $1.58.

Amount of Analyst Coverage

Actinium Pharmaceuticals has received no research coverage in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Actinium Pharmaceuticals are expected to grow in the coming year, from ($1.41) to ($0.77) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Actinium Pharmaceuticals is -1.13, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Actinium Pharmaceuticals is -1.13, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Actinium Pharmaceuticals has a P/B Ratio of 1.20. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: N/A
• Short Interest Level: N/A

Short Interest

There is no current short interest data available for ATNM.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Actinium Pharmaceuticals does not currently pay a dividend.

Dividend Growth

Actinium Pharmaceuticals does not have a long track record of dividend growth.

News and Social Media

• Score: 2.5 / 5
• News Sentiment: 0.04

News Sentiment

Actinium Pharmaceuticals has a news sentiment score of 0.04. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.55 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 6 news articles for Actinium Pharmaceuticals this week, compared to 1 article on an average week.

Search Interest

Only 2 people have searched for ATNM on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

MarketBeat Follows

1 people have added Actinium Pharmaceuticals to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 0.4 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Actinium Pharmaceuticals insiders have not sold or bought any company stock.

Percentage Held by Insiders

0.91% of the stock of Actinium Pharmaceuticals is held by insiders.

Percentage Held by Institutions

27.50% of the stock of Actinium Pharmaceuticals is held by institutions.

Company Calendar

• Today: 11/13/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NYSE
• Sector: Healthcare
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: NYSE:ATNM
• Previous Symbol: NYSE:ATNM
• CIK: 1388320
• Web: actiniumpharma.com
• Phone: (646) 677-3870
• Fax: N/A
• Employees: 25
• Year Founded: 2000

Price Target and Rating

• Average Price Target for Actinium Pharmaceuticals: $5.00
• High Price Target: $5.00
• Low Price Target: $5.00
• Potential Upside/Downside: +217.5%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 1 Analysts

Profitability

• EPS (Trailing Twelve Months): $0.36
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$48.82 million
• Net Margins: N/A
• Pretax Margin: -50,512.35%
• Return on Equity: -100.85%
• Return on Assets: -47.89%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 10.25
• Quick Ratio: 10.25

Sales & Book Value

• Annual Sales: $35.09 million
• Price / Sales: 1.41
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $1.31 per share
• Price / Book: 1.20

Miscellaneous

• Outstanding Shares: 31,441,000
• Free Float: 29,324,000
• Market Cap: $49.52 million
• Optionable: Optionable
• Beta: 0.27